PT - JOURNAL ARTICLE AU - Irene Caselles Gonzalez AU - Rubén Andújar Espinosa AU - Chushao Hu AU - Beatriz Galvez Martínez AU - Carlos Federico Álvarez Miranda AU - Olga Meca Birlanga AU - Miguel Reyes Cotes AU - Andrés Carrillo Alcaraz AU - Juan Miguel Sánchez Nieto TI - A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations AID - 10.1183/13993003.congress-2015.PA3705 DP - 2015 Sep 01 TA - European Respiratory Journal PG - PA3705 VI - 46 IP - suppl 59 4099 - http://erj.ersjournals.com/content/46/suppl_59/PA3705.short 4100 - http://erj.ersjournals.com/content/46/suppl_59/PA3705.full SO - Eur Respir J2015 Sep 01; 46 AB - Introduction: Non-pharmacological interventions in COPD can save care resources.Material and Methods: A multicentre, randomized, single-blind, parallel-group clinical trial with a one-year follow-up of a self-treatment programme (STP) versus conventional management. The STP intervention group included a group education centre, training in inhaler technique and a written treatment plan. The control group received standard care. The main variable was the severe exacerbations rate. Secondary variables were number of admissions and mortality.Results: Of the 250 patients recruited, 101 (40.4%) were included in the trial; 38 (37.62%) patients in the control group (CG) completed the trial and 47 (46.53%) in the intervention group (IG). There were no significant differences in the baseline characteristics of the patients. Twenty (52.6%) patients in the CG presented severe exacerbations vs 19 (40.4%) in the IG (P=0.262). Sixteen patients (42.1%) in the CG were hospitalised vs 12 (25.5%) in the IG (P=0.106). Two patients (5.26%) in the control group died vs none in the intervention group (P=0.383). The severe exacerbations rate was 1.37 (1.02–1.79) in the CG vs 0.89 (0.64-1.21) in the IG (P=0.049) (rate ratio, 1.53 [1.01-2.29]). The NNT (STP vs conventional treatment) to prevent one severe exacerbation per year was 6.25 (5.0-8.0).Conclusions: 1. In the first year, the STP reduced the severe exacerbations rate in patients with COPD. 2. The STP reduced the number of hospitalizations and of severe exacerbations. 3. The STP could be used in less than half of the selected population.